Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
|Articles|October 25, 2007
Refrigeration no longer necessary for Humate-P
Approval granted for change in Humate-P storage.
Advertisement
The FDA has approved changes to the labeling of antihemophilic factor/von Willebrand factor complex (human) (Humate-P, CSL Behring) following review of stability data submitted by the manufacturer. The agency determined that
Advertisement
Related to this article
Researchers assess the neurological outcomes of over 200,000 children exposed to COVID-19 before birth.
Results show consistent improvements in wakefulness, cataplexy, and quality of life with oveporexton for patients with narcolepsy.
Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.
Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.
The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
Study Finds No Neurodevelopmental Risk in Prenatal COVID-19, Except Speech
3
Oveporexton Met Primary, Key Secondary End Points in Phase 3 Studies
4
GLP-1 Prescribing Rose Among Adults With Serious Mental Illness
5